• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 6
  3. Authors

Online ISSN: 2515-8260

Volume7, Issue6

Serum Neuron Specific Enolase (NSE) as a biomarker for Hypoxic Ischemic Encephalopathy in a tertiary care hospital- A prospective study

    Dr. Debajani Panda Anup kumar Rana Dr Bibhudatta Dash Dr. Subhashree Ray Dr. Rachita Sarangi

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 6, Pages 1230-1235

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: The cause for disease and mortality throughout the infant was hypoxic ischemical encephalopathy secondary to perinatal asphyxia. It leads to permanent neuropsychological disability. Identification of a biomarker for hypoxic insult can not only help in earlier implementation of neuro-protective strategies but also in prognosticating the long term outcome.
Method: A prospective observational study conducted in IMS and SUM hospital over a period of 2 years in which 60 newborns with clinical evidence of HIE were recruited as case group. A group of 20 newborns with no evidence of HIE served as control. The serum neuron specific enolase (NSE ) levels at 4hours and 48 hours of birth of both the groups were tested and compared.
Results: The mean serum NSE levels at 4hours and 48 hours was significantly higher in the case group ( 42.43 ng/ml, 28.97 ng/ml) as compared to the control group (18.51ng/ml, 15.62ng/ml). Additionally, the mean serum NSE stages increased by the harshness of HIE in the various subgroups as per the clinical staging. ROC curve for this study has shown a good predictability for neurological outcome. For the cut off value of 40.4 mcg/l, the sensitivity was 80 % and specificity was 81.2 %.
Conclusion: Serum NSE levels can be a reliable biomarker for neurological insult in Hypoxic ischemic Encephalopathy insult in order to implement early neuroprotective strategy
Keywords:
    Neuron precise enolase Hypoxic ischemic encephalopathy
  • PDF (250 K)
  • XML
(2020). Serum Neuron Specific Enolase (NSE) as a biomarker for Hypoxic Ischemic Encephalopathy in a tertiary care hospital- A prospective study. European Journal of Molecular & Clinical Medicine, 7(6), 1230-1235.
Dr. Debajani Panda; Anup kumar Rana; Dr Bibhudatta Dash; Dr. Subhashree Ray; Dr. Rachita Sarangi. "Serum Neuron Specific Enolase (NSE) as a biomarker for Hypoxic Ischemic Encephalopathy in a tertiary care hospital- A prospective study". European Journal of Molecular & Clinical Medicine, 7, 6, 2020, 1230-1235.
(2020). 'Serum Neuron Specific Enolase (NSE) as a biomarker for Hypoxic Ischemic Encephalopathy in a tertiary care hospital- A prospective study', European Journal of Molecular & Clinical Medicine, 7(6), pp. 1230-1235.
Serum Neuron Specific Enolase (NSE) as a biomarker for Hypoxic Ischemic Encephalopathy in a tertiary care hospital- A prospective study. European Journal of Molecular & Clinical Medicine, 2020; 7(6): 1230-1235.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 394
  • PDF Download: 301
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus